Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

por Jaramillo, Sonia, Le Cornet, Lucian, Kratzmann, Markus, Krisam, Johannes, Görner, Martin, Hänel, Mathias, Röllig, Christoph, Wass, Maxi, Scholl, Sebastian, Ringhoffer, Mark, Reichart, Alexander, Steffen, Björn, Kayser, Sabine, Mikesch, Jan-Henrik, Schaefer-Eckart, Kerstin, Schubert, Jörg, Geer, Thomas, Martin, Sonja, Kieser, Meinhard, Sauer, Tim, Kriegsmann, Katharina, Hundemer, Michael, Serve, Hubert, Bornhäuser, Martin, Müller-Tidow, Carsten, Schlenk, Richard F.
Publicado 2023